PMID- 34123431
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 2090-3170 (Print)
IS  - 2090-3189 (Electronic)
IS  - 2090-3189 (Linking)
VI  - 2021
DP  - 2021
TI  - HER2 Testing Characteristics Can Predict Residual Cancer Burden following 
      Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
PG  - 6684629
LID - 10.1155/2021/6684629 [doi]
LID - 6684629
AB  - OBJECTIVES: The response to HER2-targeted neoadjuvant chemotherapy (NAC) in 
      HER2-positive (+) breast cancer can be quantified using residual cancer burden 
      (RCB) pathologic evaluation to predict relapse free/overall survival. However, 
      more information is needed to characterize the relationship between patterns of 
      HER2 testing results and response to NAC. We evaluated clinicopathologic 
      characteristics associated with RCB categories in HER2+ patients who underwent 
      HER2-directed NAC. METHODS: A retrospective chart review was conducted with Stage 
      I-III HER2+ breast cancer cases following NAC and surgical resection. HER2 
      immunohistochemistry (IHC) staining and fluorescence in situ hybridization 
      (FISH), histologic/clinical characteristics, hormone receptor status, and RCB 
      scores (RCB-0, RCB-I, RCB-II, and RCB-III) were evaluated. RESULTS: 64/151 
      (42.4%) patients with HER2+ disease had pathologic complete response (pCR). 
      Tumors with suboptimal response (RCB-II and RCB-III) were more likely to 
      demonstrate less than 100% HER2 IHC 3+ staining (p < 0.0001), lower HER2 FISH 
      copies (p < 0.0001), and lower HER2/CEP17 ratios (p = 0.0015) compared to RCB-I 
      and RCB-II responses. Estrogen receptor classification using >/=10% versus >/=1% 
      staining showed greater association with higher RCB categories. CONCLUSIONS: 
      HER2+ characteristics show differing response to therapy despite all being 
      categorized as positive; tumors with less than 100% IHC 3+ staining, lower HER2 
      FISH copies, and lower HER2/CEP17 ratios resulted in higher RCB scores.
CI  - Copyright (c) 2021 Tamera J. Lillemoe et al.
FAU - Lillemoe, Tamera J
AU  - Lillemoe TJ
AD  - Allina Health Laboratory-Hospital Pathology Associates, 800 East 28th Street, 
      Minneapolis, MN 55407, USA.
FAU - Rendi, Mara
AU  - Rendi M
AD  - Allina Health Laboratory-Hospital Pathology Associates, 800 East 28th Street, 
      Minneapolis, MN 55407, USA.
FAU - Tsai, Michaela L
AU  - Tsai ML
AD  - Allina Health System, Virginia Piper Cancer Institute Clinical Research Program, 
      800 East 28th Street, Minneapolis, MN 55407, USA.
FAU - Knaack, Monica
AU  - Knaack M
AD  - Allina Health System, Virginia Piper Cancer Institute Clinical Research Program, 
      800 East 28th Street, Minneapolis, MN 55407, USA.
FAU - Yarosh, Rina
AU  - Yarosh R
AD  - Allina Health System, Virginia Piper Cancer Institute Clinical Research Program, 
      800 East 28th Street, Minneapolis, MN 55407, USA.
FAU - Grimm, Erin
AU  - Grimm E
AD  - Allina Health Laboratory-Hospital Pathology Associates, 800 East 28th Street, 
      Minneapolis, MN 55407, USA.
FAU - Susnik, Barbara
AU  - Susnik B
AD  - Allina Health Laboratory-Hospital Pathology Associates, 800 East 28th Street, 
      Minneapolis, MN 55407, USA.
FAU - Krueger, Janet
AU  - Krueger J
AD  - Allina Health System, Virginia Piper Cancer Institute Clinical Research Program, 
      800 East 28th Street, Minneapolis, MN 55407, USA.
FAU - Olet, Susan
AU  - Olet S
AD  - Allina Health System, Research Informatics, 925 Chicago Avenue, Minneapolis, MN 
      55407, USA.
FAU - Swenson, Karen K
AU  - Swenson KK
AUID- ORCID: 0000-0002-2934-2755
AD  - Allina Health System, Virginia Piper Cancer Institute Clinical Research Program, 
      800 East 28th Street, Minneapolis, MN 55407, USA.
LA  - eng
PT  - Journal Article
DEP - 20210524
PL  - Egypt
TA  - Int J Breast Cancer
JT  - International journal of breast cancer
JID - 101568103
PMC - PMC8166502
COIS- The authors report no conflict of interest pertaining to this work.
EDAT- 2021/06/15 06:00
MHDA- 2021/06/15 06:01
PMCR- 2021/05/24
CRDT- 2021/06/14 09:45
PHST- 2020/12/28 00:00 [received]
PHST- 2021/05/09 00:00 [accepted]
PHST- 2021/06/14 09:45 [entrez]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2021/06/15 06:01 [medline]
PHST- 2021/05/24 00:00 [pmc-release]
AID - 10.1155/2021/6684629 [doi]
PST - epublish
SO  - Int J Breast Cancer. 2021 May 24;2021:6684629. doi: 10.1155/2021/6684629. 
      eCollection 2021.